Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion
Umbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients wit...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.4061/2011/276193 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562444098076672 |
|---|---|
| author | Katsuhiro Kita Jong O. Lee Celeste C. Finnerty David N. Herndon |
| author_facet | Katsuhiro Kita Jong O. Lee Celeste C. Finnerty David N. Herndon |
| author_sort | Katsuhiro Kita |
| collection | DOAJ |
| description | Umbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss several recent promising findings related to the technical improvement of cord blood transplantation. |
| format | Article |
| id | doaj-art-0dba53c291a242e9afcdc7a9d0d45f50 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-0dba53c291a242e9afcdc7a9d0d45f502025-02-03T01:22:37ZengWileyStem Cells International1687-966X1687-96782011-01-01201110.4061/2011/276193276193Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo ExpansionKatsuhiro Kita0Jong O. Lee1Celeste C. Finnerty2David N. Herndon3Department of Surgery, Shriners Hospitals for Children, University of Texas Medical Branch, 815 Market Street, Galveston, TX 77550, USADepartment of Surgery, Shriners Hospitals for Children, University of Texas Medical Branch, 815 Market Street, Galveston, TX 77550, USADepartment of Surgery, Shriners Hospitals for Children, University of Texas Medical Branch, 815 Market Street, Galveston, TX 77550, USADepartment of Surgery, Shriners Hospitals for Children, University of Texas Medical Branch, 815 Market Street, Galveston, TX 77550, USAUmbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss several recent promising findings related to the technical improvement of cord blood transplantation.http://dx.doi.org/10.4061/2011/276193 |
| spellingShingle | Katsuhiro Kita Jong O. Lee Celeste C. Finnerty David N. Herndon Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion Stem Cells International |
| title | Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion |
| title_full | Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion |
| title_fullStr | Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion |
| title_full_unstemmed | Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion |
| title_short | Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion |
| title_sort | cord blood derived hematopoietic stem progenitor cells current challenges in engraftment infection and ex vivo expansion |
| url | http://dx.doi.org/10.4061/2011/276193 |
| work_keys_str_mv | AT katsuhirokita cordbloodderivedhematopoieticstemprogenitorcellscurrentchallengesinengraftmentinfectionandexvivoexpansion AT jongolee cordbloodderivedhematopoieticstemprogenitorcellscurrentchallengesinengraftmentinfectionandexvivoexpansion AT celestecfinnerty cordbloodderivedhematopoieticstemprogenitorcellscurrentchallengesinengraftmentinfectionandexvivoexpansion AT davidnherndon cordbloodderivedhematopoieticstemprogenitorcellscurrentchallengesinengraftmentinfectionandexvivoexpansion |